Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Literature DB >> 25482134

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

M C Finazzi¹, A Carobbio², F Cervantes³, I M Isola³, A M Vannucchi⁴, P Guglielmelli⁴, A Rambaldi¹, G Finazzi¹, G Barosi⁵, T Barbui⁶.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 25482134 DOI： 10.1038/leu.2014.343

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

6 in total

1. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors: Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal: Blood Date: 2014-07-01 Impact factor: 22.113

2. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

Authors: Guido Finazzi; Alessandra Carobbio; Paola Guglielmelli; Chiara Cavalloni; Silvia Salmoiraghi; Alessandro M Vannucchi; Mario Cazzola; Francesco Passamonti; Alessandro Rambaldi; Tiziano Barbui
Journal: Blood Date: 2014-10-16 Impact factor: 22.113

3. Thrombosis in primary myelofibrosis: incidence and risk factors.

Authors: Tiziano Barbui; Alessandra Carobbio; Francisco Cervantes; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Alberto Alvarez-Larrán; Alessandro Rambaldi; Guido Finazzi; Giovanni Barosi
Journal: Blood Date: 2009-11-20 Impact factor: 22.113

4. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors: Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal: Blood Date: 2014-07-18 Impact factor: 22.113

5. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors: Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal: Blood Date: 2013-12-26 Impact factor: 22.113

6. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors: Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal: Blood Date: 2013-12-23 Impact factor: 22.113

6 in total

11 in total

Review 1. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors: Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal: J Thromb Thrombolysis Date: 2018-05 Impact factor: 2.300

Review 2. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors: Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal: Ann Hematol Date: 2017-08-14 Impact factor: 3.673

3. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Authors: F Passamonti; B Mora; T Giorgino; P Guglielmelli; M Cazzola; M Maffioli; A Rambaldi; M Caramella; R Komrokji; J Gotlib; J J Kiladjian; F Cervantes; T Devos; F Palandri; V De Stefano; M Ruggeri; R Silver; G Benevolo; F Albano; D Caramazza; E Rumi; M Merli; D Pietra; R Casalone; T Barbui; L Pieri; A M Vannucchi
Journal: Leukemia Date: 2016-11-25 Impact factor: 11.528

Review 4. SOHO State-of-the-Art Update and Next Questions: MPN.

Authors: Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal: Clin Lymphoma Myeloma Leuk Date: 2018-01

Review 5. Mutational profiling in myelofibrosis: implications for management.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Int J Hematol Date: 2019-10-19 Impact factor: 2.490

6. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.

Authors: Barbara Mora; Paola Guglielmelli; Andrew Kuykendall; Elisa Rumi; Margherita Maffioli; Francesca Palandri; Valerio De Stefano; Marianna Caramella; Silvia Salmoiraghi; Jean-Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Marco Ruggeri; Richard T Silver; Francesco Albano; Giulia Benevolo; David M Ross; Matteo G Della Porta; Timothy Devos; Giada Rotunno; Rami S Komrokji; Ilaria C Casetti; Michele Merli; Marco Brociner; Domenica Caramazza; Giuseppe Auteri; Tiziano Barbui; Daniele Cattaneo; Lorenza Bertù; Luca Arcaini; Alessandro M Vannucchi; Francesco Passamonti
Journal: Leukemia Date: 2022-08-30 Impact factor: 12.883